CN Patent

CN114539161B — 一种奥拉帕尼-尿素共晶及其制备方法

Assigned to Chengdu Shuoder Pharmaceutical Co ltd · Expires 2024-03-29 · 2y expired

What this patent protects

本发明属于药物晶型领域，提供了一种奥拉帕尼尿素新共晶及其制备方法。本发明提供的奥拉帕尼‑尿素新共晶溶解度大，稳定性好，毒性低，生物利用度良好；且制备方法简单，环保，重复性好，适合工业放大生产。

USPTO Abstract

本发明属于药物晶型领域，提供了一种奥拉帕尼尿素新共晶及其制备方法。本发明提供的奥拉帕尼‑尿素新共晶溶解度大，稳定性好，毒性低，生物利用度良好；且制备方法简单，环保，重复性好，适合工业放大生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN114539161B
Jurisdiction
CN
Classification
—
Expires
2024-03-29
Drug substance claim
No
Drug product claim
No
Assignee
Chengdu Shuoder Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.